NCT00619879已完成3 期
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- Evaluate the morbidity and mortality of hematopoietic progenitor cell transplantation (HPCT) at Children's Memorial Hospital.
研究概览
简要总结
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
详细描述
Myeloablative hematopoietic progenitor cell transplantation (HPCT) remains the standard of care for patients requiring HPCT. The purpose of this study is to evaluate the morbidity and mortality of myeloablative HPCT at Children's Memorial Hospital. It will also look to determine the toxicity of a single conditioning regimen consisting of total body irradiation (TBI), etoposide (VP-16), and Cyclophosphamide for patients with transplant eligible lymphoid malignant conditions or with transplant eligible myeloid malignant conditions who are receiving cord blood units, or to determine the toxicity of a single conditioning regimen consisting of Busulfan and Cyclophosphamide for patients with transplant eligible myeloid malignant conditions who are not receiving cord blood units.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Malignant Disease
- •Chronic myleogenous leukemia in chronic or accelerated phase
- •Acute lymphoblastic leukemia (ALL)
- •First remission high-risk ALL (Ph+, t( 4-11) infants).
- •Second remission ALL, after a short first remission (<36 mos from Dx).
- •3rd or greater remission ALL.
- •Acute myelogenous leukemia (AML)
- •First remission high risk acute nonlymphoblastic (ANLL) (as defined by cytogenetics), if a matched sibling donor is available.
- •Initial partial remission AML (<20% blasts in the bone marrow).
- •AML that is refractory to two cycles of induction therapy.
- •Second or greater remission AML
- •Myelodysplastic/Myeloproliferative Disease
- •Juvenile Myelomonocytic Leukemia (JMML)
- •Myelosplastic syndrome and/or pre-leukemia at any stage
- •Relapsed lymphoma with residual disease that appears to be chemo-sensitive and non-bulky (<5 cm at largest diameter)
- •Venous Access: Three lumens of central vascular access will be required for all patients entered on protocol due to the need for a dedicated line for continuous infusion cyclosporine.
- •Informed Consent: The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained in accordance with the institutional policies approved by the U.S. Department of Health and Human Services.
- •Patient organ function requirements:
- •Adequate renal function: Serum Creatinine <~1.5 x normal, or Creatinine clearance of 70 mL/min/1.73 mE2 or an equivalent GFR as determined by the institutional normal range
- •Adequate liver function: Total bilirubin <1.5 x normal; and SGOT (AST) or SGPT (ALT) <~2.5 x normal
- •Adequate cardiac function: Shortening fraction of >/=27% by echocardiogram
- •Adequate pulmonary function: FEV1/FVC >/=60% by pulmonary function test; for children who are uncooperative, no evidence of dysnpea at rest, or exercise intolerance, and must have a pulse oximetry >94% in room air
- •Performance status: Lansky for children </= 16 years >/= 60; Karnofsky status for those > 16 years of age >/= 70
- •Effective Contraceptive Use: Women of childbearing potential and sexually active males should use effective contraception while on study.
排除标准
- •Patients who are pregnant or lactating
- •Inability to find a suitable donor for the patient
- •Patient is HIV-positive
- •Patient has active Hepatitis B
- •Disease progression or relapse prior to HPC infusion
结局指标
主要结局
Evaluate the morbidity and mortality of hematopoietic progenitor cell transplantation (HPCT) at Children's Memorial Hospital.
时间窗: To study end
次要结局
- Evaluate the effectiveness of graft versus host disease prevention with a combination of anti-thymocyte globulin, continuous infusion cyclosporine, and short course methotrexate for transplants.(To study end)
- Determine the toxicity of a single conditioning regimen consisting of total body irradiation, etoposide, and Cyclophosphamide for patients with transplant eligible lymphoid malignant conditions or myeloid malignant conditions receiving cord blood units.(To study end)
- Determine the toxicity of a single conditioning regimen consisting of Busulfan and Cyclophosphamide for patients with transplant eligible myeloid malignant conditions who are not receiving cord blood units.(To study end)
研究者
Sonali Chaudhury, MD
Principal Investigator
Ann & Robert H Lurie Children's Hospital of Chicago
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Unrelated Donor Stem Cell TransplantationParoxysmal Nocturnal HemoglobinuriaAcute Myelogenous LeukemiaMyelodysplastic SyndromesMyeloproliferative SyndromesAcute Lymphoblastic LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaSmall Lymphocytic LymphomaLarge Granulocytic LeukemiaMultiple MyelomaChronic Lymphocytic LeukemiaSevere Aplastic AnemiaChronic Myelogenous LeukemiaNCT01364363Scripps Health64
已完成
2 期
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete RemissionAdult Acute Lymphoblastic Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaNCT00031655Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium30
招募中
2 期
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPlasma Cell LeukemiaMyeloproliferative NeoplasmsMyelodysplasiaHigh Risk AnemiaSmall Lymphocytic LymphomaLymphomaAcute Myeloid LeukemiaChronic Myelogenous LeukemiaMarginal Zone B-Cell LymphomaJuvenile Myelomonocytic LeukemiaLymphoplasmacytic LymphomaMantle-Cell LymphomaDiffuse Large Cell Non Hodgkins LymphomaLymphoblastic LymphomaBurkitt LymphomaHigh Grade Non-Hodgkin's Lymphoma, AdultMultiple MyelomaProlymphocytic LeukemiaBiphenotypic/Undifferentiated/Prolymphocytic LeukemiasMRD Positive LeukemiaNatural Killer Cell MalignanciesAcquired Bone Marrow Failure SyndromesAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaRefractory AnemiaMyelofibrosisAcute LeukemiaFollicular LymphomaNCT03314974Masonic Cancer Center, University of Minnesota300
已完成
2 期
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow MalignancesImmunosuppressionLeukemiaNCT00353860National Heart, Lung, and Blood Institute (NHLBI)70
已完成
2 期
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow MalignanciesHematologic MalignanciesBone Marrow Transplant RejectionNCT00079391National Heart, Lung, and Blood Institute (NHLBI)50